Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine

Vaccine

Volumn 27, Issue 49, 2009, Pages 6845-6853

  Awasthi, Sita ^a   Lubinski, John M ^a   Friedman, Harvey M ^a  

^a School of Veterinary Medicine   (United States)

Author keywords

Glycoprotein C; HSV vaccine; Immune evasion

Indexed keywords

ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3B; FREUND ADJUVANT; GLYCOPROTEIN; GLYCOPROTEIN C1; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; HSV 1 GLYCOPROTEIN C SUBUNIT VACCINE; HSV 1 GLYCOPROTEIN D SUBUNIT VACCINE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN C;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; PRIORITY JOURNAL; PURIFICATION; SPINAL GANGLION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; COMPLEMENT C3B; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GANGLIA, SPINAL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; IMMUNE EVASION; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS; VACCINES, SUBUNIT; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 70350569985     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.017     Document Type: Article

References (47)

1. Carroll M.C. The role of complement in B cell activation and tolerance. Adv Immunol 74 (2000) 61-88
2. Fang C., Miwa T., Shen H., and Song W.C. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J Immunol 179 5 (2007) 3178-3186
3. Kopf M., Abel B., Gallimore A., Carroll M., and Bachmann M.F. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8 4 (2002) 373-378
4. Lachmann P.J., and Davies A. Complement and immunity to viruses. Immunol Rev 159 (1997) 69-77
5. Mehlhop E., and Diamond M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Expert Med 203 5 (2006) 1371-1381
6. Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28 3 (2008) 425-435
7. Eisenberg R.J., Ponce de Leon M., Friedman H.M., Fries L.F., Frank M.M., Hastings J.C., et al. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathogen 3 6 (1987) 423-435
8. Friedman H.M., Cohen G.H., Eisenberg R.J., Seidel C.A., and Cines D.B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature 309 5969 (1984) 633-635
9. Friedman H.M., Wang L., Pangburn M.K., Lambris J.D., and Lubinski J. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol 165 8 (2000) 4528-4536
10. Kostavasili I., Sahu A., Friedman H.M., Eisenberg R.J., Cohen G.H., and Lambris J.D. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol 158 4 (1997) 1763-1771
11. Lubinski J.M., Wang L., Soulika A.M., Burger R., Wetsel R.A., Colten H., et al. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 72 10 (1998) 8257-8263
12. McNearney T.A., Odell C., Holers V.M., Spear P.G., and Atkinson J.P. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med 166 5 (1987) 1525-1535
13. Harris S.L., Frank I., Yee A., Cohen G.H., Eisenberg R.J., and Friedman H.M. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis 162 2 (1990) 331-337
14. Hung S.L., Srinivasan S., Friedman H.M., Eisenberg R.J., and Cohen G.H. Structural basis of C3b binding by glycoprotein C of herpes simplex virus. J Virol 66 7 (1992) 4013-4027
15. Lubinski J., Wang L., Mastellos D., Sahu A., Lambris J.D., and Friedman H.M. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med 190 11 (1999) 1637-1646
16. Lubinski J.M., Jiang M., Hook L., Chang Y., Sarver C., Mastellos D., et al. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J Virol 76 18 (2002) 9232-9241
17. Chang Y.J., Jiang M., Lubinski J.M., King R.D., and Friedman H.M. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains. Vaccine 23 38 (2005) 4658-4665
18. Judson K.A., Lubinski J.M., Jiang M., Chang Y., Eisenberg R.J., Cohen G.H., et al. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection. J Virol 77 23 (2003) 12639-12645
19. Byars N.E., Fraser-Smith E.B., Pecyk R.A., Welch M., Nakano G., Burke R.L., et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 12 3 (1994) 200-209
20. Da Costa X.J., Morrison L.A., and Knipe D.M. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 288 2 (2001) 256-263
21. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16 1 (2003) 96-113
22. Meignier B., Martin B., Whitley R.J., and Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162 2 (1990) 313-321
23. Nass P.H., Elkins K.L., and Weir J.P. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 19 11-12 (2001) 1538-1546
24. Strasser J.E., Arnold R.L., Pachuk C., Higgins T.J., and Bernstein D.I. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 182 5 (2000) 1304-1310
25. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 21 (2002) 1652-1661
26. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas Jr. J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282 4 (1999) 331-340
27. Brittle E.E., Wang F., Lubinski J.M., Bunte R.M., and Friedman H.M. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol 82 17 (2008) 8431-8441
28. Friedman H.M., Wang L., Fishman N.O., Lambris J.D., Eisenberg R.J., Cohen G.H., et al. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 70 7 (1996) 4253-4260
29. Cohen G.H., Isola V.J., Kuhns J., Berman P.W., and Eisenberg R.J. Localization of discontinuous epitopes of herpes simplex virus glycoprotein D: use of a nondenaturing ("native" gel) system of polyacrylamide gel electrophoresis coupled with Western blotting. J Virol 60 1 (1986) 157-166
30. Muggeridge M.I., Isola V.J., Byrn R.A., Tucker T.J., Minson A.C., Glorioso J.C., et al. Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol 62 9 (1988) 3274-3280
31. Sisk W.P., Bradley J.D., Leipold R.J., Stoltzfus A.M., Ponce de Leon M., Hilf M., et al. High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J Virol 68 2 (1994) 766-775
32. Tal-Singer R., Peng C., Ponce De Leon M., Abrams W.R., Banfield B.W., Tufaro F., et al. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 69 7 (1995) 4471-4483
33. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25 7 (2007) 1214-1224
34. Nagashunmugam T., Lubinski J., Wang L., Goldstein L.T., Weeks B.S., Sundaresan P., et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 72 7 (1998) 5351-5359
35. Awasthi S., Lubinski J.M., Eisenberg R.J., Cohen G.H., and Friedman H.M. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 26 9 (2008) 1195-1203
36. Da Costa X.J., Brockman M.A., Alicot E., Ma M., Fischer M.B., Zhou X., et al. Humoral response to herpes simplex virus is complement-dependent. Proc Nat Acad Sci USA 96 22 (1999) 12708-12712
37. Lopez C. Genetics of natural resistance to herpesvirus infections in mice. Nature 258 5531 (1975) 152-153
38. Lin X., Lubinski J.M., and Friedman H.M. Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor. J Virol 78 5 (2004) 2562-2571
39. Johansson P.J., Myhre E.B., and Blomberg J. Specificity of Fc receptors induced by herpes simplex virus type 1: comparison of immunoglobulin G from different animal species. J Virol 56 2 (1985) 489-494
40. Huemer H.P., Larcher C., van Drunen Littel-van den Hurk S., and Babiuk L.A. Species selective interaction of Alphaherpesvirinae with the "unspecific" immune system of the host. Arch Virol 130 3-4 (1993) 353-364
41. Herold B.C., WuDunn D., Soltys N., and Spear P.G. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol 65 3 (1991) 1090-1098
42. Kohl S., West M.S., Prober C.G., Sullender W.M., Loo L.S., and Arvin A.M. Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis 160 5 (1989) 770-776
43. Hoshino Y., Pesnicak L., Cohen J.I., and Straus S.E. Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells. J Virol 81 15 (2007) 8157-8164
44. Lekstrom-Himes J.A., Wang K., Pesnicak L., Krause P.R., and Straus S.E. The comparative biology of latent herpes simplex virus type 1 and type 2 infections: latency-associated transcript promoter activity and expression in vitro and in infected mice. J Neurovirol 4 1 (1998) 27-37
45. Sawtell N.M., Thompson R.L., Stanberry L.R., and Bernstein D.I. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 184 8 (2001) 964-971
46. Thompson R.L., and Sawtell N.M. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J Virol 75 14 (2001) 6660-6675
47. Wachsman M., Kulka M., Smith C.C., and Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19 15-16 (2001) 1879-1890